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Vascular Medicine
Chronic Thromboembolic Pulmonary
Hypertension (CTEPH)
Results From an International Prospective Registry
Joanna Pepke-Zaba, MD; Marion Delcroix, MD; Irene Lang, MD; Eckhard Mayer, MD;
Pavel Jansa, MD; David Ambroz, MD; Carmen Treacy, BSc; Andrea M. D’Armini, MD;
Marco Morsolini, MD; Repke Snijder, MD; Paul Bresser, MD; Adam Torbicki, MD;
Bent Kristensen, MD; Jerzy Lewczuk, MD; Iveta Simkova, MD; Joan A. Barbera`, MD;
Marc de Perrot, MD; Marius M. Hoeper, MD; Sean Gaine, MD; Rudolf Speich, MD;
Miguel A. Gomez-Sanchez, MD; Gabor Kovacs, MD; Abdul Monem Hamid, MD;
Xavier Jaı¨s, MD; Ge´rald Simonneau, MD
Background—Chronic thromboembolic pulmonary hypertension (CTEPH) is often a sequel of venous thromboembolism
with fatal natural history; however, many cases can be cured by pulmonary endarterectomy. The clinical characteristics
and current management of patients enrolled in an international CTEPH registry was investigated.
Methods and Results—The international registry included 679 newly diagnosed (6 months) consecutive patients with
CTEPH, from February 2007 until January 2009. Diagnosis was confirmed by right heart catheterization, ventilation-
perfusion lung scintigraphy, computerized tomography, and/or pulmonary angiography. At diagnosis, a median of 14.1
months had passed since first symptoms; 427 patients (62.9%) were considered operable, 247 (36.4%) nonoperable, and
5 (0.7%) had no operability data; 386 patients (56.8%, ranging from 12.0%– 60.9% across countries) underwent surgery.
Operable patients did not differ from nonoperable patients relative to symptoms, New York Heart Association class, and
hemodynamics. A history of acute pulmonary embolism was reported for 74.8% of patients (77.5% operable, 70.0%
nonoperable). Associated conditions included thrombophilic disorder in 31.9% (37.1% operable, 23.5% nonoperable)
and splenectomy in 3.4% of patients (1.9% operable, 5.7% nonoperable). At the time of CTEPH diagnosis, 37.7% of
patients initiated at least 1 pulmonary arterial hypertension–targeted therapy (28.3% operable, 53.8% nonoperable).
Pulmonary endarterectomy was performed with a 4.7% documented mortality rate.
Conclusions—Despite similarities in clinical presentation, operable and nonoperable CTEPH patients may have distinct
associated medical conditions. Operability rates vary considerably across countries, and a substantial number of patients
(operable and nonoperable) receive off-label pulmonary arterial hypertension–targeted treatments. (Circulation. 2011;
124:1973-1981.)
Key Words: hypertension, pulmonary  endarterectomy  chronic disease
Chronic thromboembolic pulmonary hypertension(CTEPH) most often results from obstruction of the
pulmonary vascular bed by nonresolving thromboemboli.
Chronic thromboembolic pulmonary hypertension can arise
in patients after acute or recurrent pulmonary emboli or deep
venous thrombosis.1,2 Increased pulmonary vascular resis-
tance (PVR) subsequently leads to progressive pulmonary
hypertension and right heart failure. In the nonoccluded areas,
a pulmonary arteriopathy indistinguishable from that of
pulmonary arterial hypertension (PAH) can develop and
contribute to disease progression.3 The incidence of CTEPH
is not known, but recent studies suggest that 1% to 3.8% of
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patients develop the condition within 2 years of acute
pulmonary embolism.4,5 Without intervention, the prognosis
of patients with CTEPH is poor and depends on the hemo-
dynamic severity of pulmonary hypertension.6,7
Clinical Perspective on p 1981
Progress in surgical and medical treatment over the past
decade has considerably improved the outcome of CTEPH
patients. The only potentially curative treatment is surgical
removal of the obstructive material by pulmonary endarter-
ectomy (PEA).8 However, a substantial percentage of patients
with CTEPH are not operable, and 10% to 15% of operated
patients suffer from persistent pulmonary hypertension.9
These patients may benefit from PAH-targeted therapies.10–13
Previously, retrospective data have been collected from 4
European referral centers for CTEPH from Austria, Czech
Republic, Germany, and Slovak Republic,14 and a national
CTEPH registry was established in the United Kingdom.15
Here, we present short-term data from the first prospective,
large-scale, international registry of patients with CTEPH
including operable and nonoperable cases. We describe
history and current diagnostic and treatment procedures of
newly diagnosed CTEPH patients and potential associated
conditions.
Methods
Study Design
This prospective registry was designed to include newly diagnosed
(6 months) consecutive patients with CTEPH who did not receive
PAH-targeted treatment before diagnosis from centers in Europe and
Canada between February 2007 and January 2009. The registry
protocol did not interfere with the management of patients by their
physician. Formal ethics approvals were obtained when required by
the country’s regulatory agency. The observation period was from
study inclusion until death/transplantation or data analysis cut off
(December 2009). Long-term follow-up is on-going.
Inclusion Criteria
At all participating institutions, the diagnosis of CTEPH was
established according to clinical guidelines valid at study initiation16
and within 6 months of inclusion in the registry. To qualify for
inclusion, patients had to be 18 years of age and pulmonary
hypertension was to be confirmed by right heart catheterization16
indicating a mean pulmonary artery pressure (mPAP)25 mm Hg at
rest or 30 mm Hg after exercise and a pulmonary capillary wedge
pressure 15 Chronic thromboembolic pulmonary hyperten-
sion mm Hg (or 15 mm Hg if justified).
Chronic thromboembolic pulmonary hypertension was to be
confirmed as the cause of pulmonary hypertension by abnormalities
in ventilation/perfusion scan (at least 1 mismatched segmental
perfusion defect), computed tomography (CT) scan, and/or in pul-
monary angiography. Proximal lesions (webs, bands, and narrowed
vessels) were identified by CT scan/pulmonary angiography. Before
diagnosis, patients were required to have at least 3 months of
anticoagulation therapy and no PAH-targeted treatment.
Data Collection
Data were obtained from assessments that are routinely performed
for CTEPH patients in clinical practice including medical history,
clinical signs and symptoms, diagnosis, and treatment procedures.
Surgery
The PEA procedure has been described previously.8,17 Criteria for
nonoperability included distal pulmonary artery obstructions,
imbalance between increased PVR and amount of accessible
occlusions suggesting microvascular disease, PVR 1500
dyn  s  cm5, age, and comorbidity. Persistent pulmonary hyper-
tension after PEA was defined as mPAP 25 mm Hg by right
heart catheterization or systolic pulmonary arterial pressure
40 mm Hg by echocardiography.
Statistical Analysis
Data were analyzed with the SAS software package version 9.2.
Results are expressed as medians with first and third quartiles
(Q1–Q3) or numbers and percentages of patients with the assess-
ment. Operable and nonoperable patients were compared using the
Wilcoxon rank-sum test for continuous variables and the Fisher
exact test for categorical variables. The reported P values are to
be interpreted in the exploratory sense.
Results
Study Population
Between February 2007 and January 2009, 679 consecutive
patients with recently diagnosed (6 months) CTEPH were
prospectively enrolled in 26 European centers and 1 Canadian
center across 16 different countries. At the time of data
cut-off, patients had been included for a minimum of 10
months; for 107 patients, follow-up in the registry was
terminated because of death (n62), transplantation (n1),
move to another center (n35), loss of follow-up (n4),
patient’s request (n3), and other reasons (n2). On the
basis of the surgeon’s assessment, 427 patients (63.3%) were
considered operable and 247 (36.6%) nonoperable (5 patients
missing data). Nonoperability was due to inaccessibility of
the occlusions (n118), imbalance between increased PVR
and amount of accessible occlusions (n25), PVR 1500
dyn  s  cm5 (n6), age (n5), comorbidities (n33), or
other reason (n56) (4 patients missing data). The patient
population was divided per treatment intention into 2 groups:
operable and nonoperable. At the time of data cut-off, 386
patients (56.8%) had undergone surgery (these operated
patients have been described elsewhere17); 37 operable pa-
tients had refused the procedure and did not have surgery and
7 had died before surgery (the Figure).
The characteristics of the patient population at inclusion
are summarized in Table 1. The median age was 63 years, and
50.1% were men. The operable group was younger (median:
61 years) and included more men (53.4%) than the nonoper-
able group.
Most patients consulted first a pulmonologist (35.1%) or a
cardiologist (34.4%) (n678). At the time of CTEPH diag-
nosis, a median of 14.1 months had passed since the first
symptoms were observed (Q1–Q3: 7.5–32.8 months,
n637): 14.9 months for operable and 13.1 month for
nonoperable patients (P0.4051). The median time from last
acute pulmonary embolism to CTEPH diagnosis was 12.5
months (Q1–Q3: 5.7–33.6 months, n448): 12.0 months for
operable and 13.9 months for nonoperable patients
(P0.3609). Most common presenting symptoms were: dys-
pnea (99.1%), edema (40.5%), fatigue (31.5%), chest pain
(15.3%), or syncope (13.7%) (n676). At diagnosis, the
majority of patients were in NYHA functional class III or IV.
Operable patients did not differ from nonoperable patients
relative to symptoms and NYHA class, although their walk-
ing distance tended to be higher, which could also be
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associated with younger age (Table 1). Hematologic, bio-
chemical and pulmonary function parameters were similar in
both groups. Overall, blood group non-0 was more frequent
(76.0% overall; 79.5% operable, 68.4% nonoperable patients,
P0.0255) than observed for the general population (45%–
70% in Europe and Canada).
Previous pulmonary embolism was confirmed for 74.8% of
all patients, and was more frequent and recurrent in the
operable group of patients (Table 2). In this group, more
patients had previous massive pulmonary embolism. Previous
deep vein thrombosis was observed in 56.1% of patients and
was also more common in the operable group of patients
(Table 2). After an acute pulmonary embolism or deep vein
thrombosis event, patients received anticoagulants, including
oral anticoagulants (n492/519), low molecular weight hep-
arin (n23), unfractionated heparin (n3), and/or other
(n16). Thrombolytic treatment was initiated in 14.4% of
patients and a vena cava filter or clip was placed in 12.4% of
patients as prevention for recurrent pulmonary embolism.
Operable patients had more frequently been treated with
thrombolytics possibly because of the high incidence and
severity of pulmonary embolism (Table 2).
An additional cause potentially contributing to pulmonary
hypertension was documented in 20.9% of patients (Table 3).
This percentage was lower for the operable group (17.1%)
than for the nonoperable group (27.2%). In both groups, the
most frequent associated condition was chronic obstructive
pulmonary disease. The occurrence of medical conditions
known previously to be associated with pulmonary embolism
and CTEPH is listed in Table 4. A thrombophilic disorder and
a family history of deep vein thrombosis or pulmonary
embolism were more frequent in the operable group, whereas
previous splenectomy, major surgery, congestive heart failure
and a history of cancer were more frequent in the nonoperable
group (Table 4). A history of cancer was reported for over
12% of the patients (10.1% operable and 16.6% nonoperable
patients). Among 426 assessed patients, 118 (27.7%) had at
least one established thrombotic risk factor including lupus
anticoagulant/antiphospholipid antibodies (10.1%), protein S
and C deficiency (9.6%; 8.9%), activated protein C resistance
including Factor V Leiden mutation (7.7%), prothrombin
gene mutation (3.5%), and antithrombin III deficiency
(0.7%). At least one of these risk factors was documented in
30.5% of operable patients and in 22.3% of nonoperable
patients (P0.0839). In addition, Factor VIII was elevated in
some patients (150% Factor VIII230% (n19, 4.5%), or
Factor VIII 230% (n14, 3.3%)).
CTEPH Diagnosis
The diagnostic evaluations are presented in Table 5. Right
heart catheterization data indicated clinically significant pul-
monary hypertension with elevated PVR (median: 709 dyn 
Recruited
n = 679
Non-operable
n = 247
Operable
n = 427
Operated
n = 373
Non-operated
n = 54
7 died
37 refused surgery
10 waiting for surgery
Non-operated
n = 234
Operated*
n = 13
Operated
n = 386 (56.8%)
5 patients with no operability data (non-operated)
Figure. Patient disposition. Operable/nonoperable
patients are assessed as such at diagnosis by the
PEA surgeon according to predefined criteria (see
Methods). Operated patients are those patients
who effectively underwent surgery. *These patients
initially deemed nonoperable were operated on.
Table 1. Patients’ Characteristics at Diagnosis
All Patients
(n679)
Operable Patients*
(n427)
Nonoperable Patients*
(n247)
P
(Exploratory)
Gender, % male 50.1 53.4 44.5 0.0308
Ethnicity, % white 95.9 95.3 96.7 0.4277
Age, y, median [Q1;Q3] 63 51; 72 61 48; 70 67 57; 74 0.0001
Weight, kg, median [Q1;Q3] 75 65; 87 76 66; 88 73 63; 82 0.0161
NYHA class, % I/II/III/IV 0.7/17.8/68.6/12.8 0.5/19.2/67.7/12.6 1.2/15.8/70.4/12.6 0.4922
6MWD, m, median Q1; Q3 (n) 329 245; 427 (589) 340 250; 435 (373) 315 223; 400 (214) 0.0219
Blood group non-0, % (n) 76.0 (366) 79.5 (249) 68.4 (117) 0.0255
Values are expressed as medians with first and third quartiles (Q1; Q3) or percentages; (n): patients with assessment; P values from
Wilcoxon rank-sum test or Fisher exact test. NYHA indicates new York Heart Association; 6MWD, 6-minute walking distance.
*Five patients had no data on operability.
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s  cm5, mean: 782 dyn  s  cm5) and mPAP (median and
mean: 47 mm Hg). In 69 patients, the pulmonary capillary
wedge pressure was found to be 15 mm Hg. These patients
were nevertheless included in the registry as in the presence
of major vessel obstructions, the assessment of wedge pres-
sure may be difficult, or sometimes impossible.18
Ventilation-perfusion lung scintigraphy showed abnormal
perfusion scans in 98.7% of patients, whereas ventilation
scans were abnormal in 19.0%. Pulmonary angiography
demonstrated proximal lesions of the pulmonary artery in
63.0% of patients. Similar results were observed with CT
pulmonary angiography, which indicated proximal lesions of
the pulmonary artery in 60.4% of patients and also dilatation
of bronchial arteries in 68.4% of patients. High resolution CT
scan demonstrated mosaic perfusion pattern in 76.6% of
patients. Proximal lesions and mosaic perfusion pattern were
less common in the nonoperable patients.
Echocardiography revealed an enlarged right ventricle in
86.7% of patients (559/645) and abnormal right ventricular
contractility in 66.7% (400/600).
Treatment at Diagnosis
At CTEPH diagnosis, 37.9% of the patients initiated at least
one PAH-targeted therapy including phosphodiesterase type
V inhibitor, endothelin receptor antagonist or prostacyclin
analog (Table 6). The operable group received less PAH-
targeted treatments than the nonoperable group (28.3% versus
53.8%; P0.0001).
Surgery
Surgical management and risk factors for in-hospital and
1-year death have been presented elsewhere in detail.17
Briefly, out of 384 assessed operated patients, 189 (49.2%)
had a perioperative complication; 18 (4. 7%) patients died in
hospital. After surgery, hemodynamics were markedly im-
proved for patients with an assessment within 1 year after PEA:
the median PVR decreased from 736 dyn  s  cm5 before
surgery to 248 dyn  s  cm5 at the end of intensive care (Q1-Q3:
530–1010 and 180–398 dyn  s  cm5, respectively, n252)
and from 698 dyn  s  cm5 before surgery to 235 dyn  s  cm5
within 1 year after surgery (Q1–Q3: 501–989 and 178–320 dyn 
s  cm5, respectively, n70).
Per Country Analyses
The demography and management characteristics were col-
lected for patients living in 16 countries, and, not surpris-
ingly, differences were observed between individual coun-
tries. The median patient age in some countries could be as
low as 55 years or as high as 68 years, and the percentage of
men varied from 30.4% to 66.7%. Furthermore, the percent-
age of patients starting PAH-targeted treatment at diagnosis
varied from 2.2% to 88.9%. The ranges for time from
symptoms to diagnosis and to surgery were respectively 12 to
22 months and 12 to 116 days. A wide variation in nonop-
erability was observed between countries (from 12.0%–
60.9%). Low-volume centers performing no or up to 10 PEAs
per year (based on data from 2004–2006) reported a higher
Table 2. Patients’ History of Venous Thromboembolism
All
Patients
(n679)
Operable
Patients*
(n427)
Nonoperable
Patients*
(n247)
P
(Exploratory)
Confirmed
previous acute
PE, % (n)
74.8 (678) 77.5 (427) 70.0 (247) 0.0344
PE diagnosed
more than
once, % (n)
32.8 (469) 35.0 (303) 28.8 (163) 0.2145
Size of previous
PE reported as
massive, % (n)
40.8 (240) 47.1 (155) 29.4 (85) 0.0090
Confirmed
previous DVT,
% (n)
56.1 (426) 60.4 (280) 49.0 (143) 0.0295
Acute PE and
DVT, % (n)
55.4 (413) 59.3 (270) 48.9 (141) 0.0477
Acute PE no
DVT, % (n)
42.6 (413) 39.3 (270) 48.2 (141) 0.0926
Thrombolytic
treatment,
% (n)
14.4 (404) 18.5 (265) 6.6 (137) 0.0009
Vena cava filter
implanted, % (n)
12.4 (491) 13.7 (322) 10.2 (166) 0.3139
P values from Fisher exact test. (n): patients with assessment. DVT indicates
deep vein thrombosis; PE, pulmonary embolism.
*5 patients had no data on operability.
Table 3. Other Reported Cause for PH at Diagnosis
All Patients
(n679)
Operable Patients*
(n427)
Nonoperable Patients*
(n247)
P
(Exploratory)
Other reported cause for PH, % (n)† 20.9 (675) 17.1 (427) 27.2 (246) 0.0022
COPD, % 9.5 8.4 11.0 0.2753
Sleep disorder breathing, % 3.1 2.1 4.9 0.0636
Left ventricular diastolic dysfunction, % 1.9 0.9 3.7 0.0188
Left-sided valvular heart disease, % 1.6 0.5 3.7 0.0027
Interstitial lung disease, % 1.3 0.7 2.4 0.0806
Drugs/toxins, % 1.5 1.2 2.0 0.5097
P values from the Fisher exact test. (n): patients with assessment. PH indicates pulmonary hypertension; COPD, chronic obstructive
pulmonary disease.
*Five patients had no data on operability.
†Cause for PH is reported if occurrence is 1.5% in any patient group.
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percentage of nonoperable patients (47.1% out of n172)
than intermediate centers performing 11 to 50 PEAs per year
(31.5%, n295) or high-volume centers performing 50
PEAs per year (34.4%, n212) (P0.0008), suggesting that
center expertise may have influenced the decision to operate.
However, further investigation would be necessary to ascer-
tain the reasons for the variability observed in operability
rates because a referral bias may also have affected the largest
surgical centers.
Death/Transplantation
At the end of the observation period, 1 patient was docu-
mented as transplanted and 62 as dead. Most frequent causes
for death were perioperative complications (n18) and right
Table 4. Associated Medical Conditions at Diagnosis
All Patients
(n679)
Operable Patients*
(n427)
Nonoperable Patients*
(n247)
P
(Exploratory)
Associated conditions, % (n) 78.4 (677) 77.0 (426) 80.6 (247) 0.2878
Thrombophilic disorder, % 31.9 37.1 23.5 0.0003
Previous major surgery, % 21.7 18.8 26.7 0.0197
Varicose veins, % 20.8 20.4 21.1 0.8440
Obesity, % 17.6 16.7 19.0 0.4623
Chronic venous insufficiency, % 15.5 16.0 14.6 0.6596
Prolonged hospitalization, % 16.0 16.0 15.8 1.0000
History of cancer, % 12.7 10.1 16.6 0.0156
Coronary disease and/or myocardial infarction, % 11.8 11.0 13.4 0.3883
Thyroid disorder and hormone replacement therapy, % 8.4 7.7 9.3 0.4732
Family history of DVT or PE, % 6.6 8.2 4.0 0.0382
Fracture, % 5.5 5.9 4.5 0.4815
Non–insulin-dependent diabetes mellitus, % 5.2 5.4 4.9 0.8580
Congestive heart failure, % 4.6 2.8 7.7 0.0065
Splenectomy, % 3.4 1.9 5.7 0.0118
Ventriculoatrial shunt, % 0.9 0.7 1.2 0.6743
Inflammatory bowel disease, % 0.7 1.2 0 0.1641
Infection of ventriculoatrial shunt or pacemaker, % 0 0 0 …
P values from Fisher exact test. (n): patients with assessment. DVT indicates deep vein thrombosis; PE, pulmonary embolism.
*Five patients had no data on operability.
Table 5. Diagnosis Evaluations
All Patients
(n679)
Operable Patients*
(n427)
Nonoperable Patients*
(n247)
P
(Exploratory)
Right heart catheterization
mPAP†, mm Hg, median Q1; Q3 (n) 47 38; 55 (669) 47 38; 55 (423) 47 38; 55 (244) 0.5064
PVR‡, dyn  s  cm5, median Q1; Q3 (n) 709 480; 988 (604) 717 495; 963 (381) 691 426; 1051 (221) 0.7408
Cardiac index, L  min1  m2 median [Q1;Q3] (n) 2.2 1.8; 2.7 (632) 2.2 1.8; 2.7 (404) 2.3 1.8; 2.8 (227) 0.1343
Scintigraphy, % (n)
Perfusion scan abnormal 98.7 (535) 99.4 (344) 97.4 (189) 0.1031
Ventilation scan abnormal 19.0 (484) 17.5 (314) 22.0 (168) 0.2736
Angiography, % (n)
Proximal lesions 63.0 (552) 70.9 (358) 48.2 (191) 0.0001
CT scan, % (n)
Proximal lesions 60.4 (541) 70.1 (345) 43.0 (193) 0.0001
Dilation of bronchial arteries 68.4 (345) 75.0 (216) 57.0 (128) 0.0008
Mosaic perfusion pattern 76.6 (414) 82.4 (261) 67.1 (152) 0.0007
P values from Wilcoxon rank-sum test or Fisher exact test. (n): patients with assessment. CT indicates computed tomography; mPAP, mean
pulmonary arterial pressure; and PVR, pulmonary vascular resistance.
*Five patients had no data on operability.
†mPAP: 12 values 25 mm Hg; 4 values 75 mm Hg.
‡PVR: 13 values 200 dyn  s  cm5.
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heart failure (n17). Comparison between the operable and
nonoperable patient groups will be performed once 3-year
follow-up data are available.
Discussion
With 679 patients included from Europe and Canada, the present
prospective registry represents the largest contemporary popula-
tion of patients with CTEPH, including newly diagnosed oper-
able and nonoperable cases. The aim of the current report is to
describe the disease at presentation along with short-term out-
come; long-term follow-up is currently ongoing. The main
findings are differences in occurrence of associated medical
conditions between operable and nonoperable patients despite
similarities in disease presentation, suggesting that these patients
represent 2 distinct subpopulations.
Although PEA is the acknowledged treatment of choice for
CTEPH, between 10% and 50% of referred patients may not
be eligible for this procedure.19 In the current registry, 36.6%
of the evaluated patients (n674) were assessed as nonoper-
able, with a large variation between countries (from 12.0% to
60.9%). Criteria for surgical suitability have been described,20
but remain expertise dependent and ill-defined as there is
currently no consensus among experts about the definition of
proximal CTEPH, potentially curable with surgery, and distal
CTEPH, presumably associated with small vessel arteriopa-
thy and poor surgical outcome.21
The registry results support the thromboembolic cause of
CTEPH, with 74.8% of patients presenting with previous
acute pulmonary embolism and 56.1% with previous deep
vein thrombosis. This is in agreement with recent studies,14,18
but contrasts with previous retrospective reports indicating no
history of venous thromboembolism in 40% to 60% of the
patients.22–24 Increased awareness of thromboembolism in the
participating registry centers may have contributed to higher
detection. As previously documented,18 a history of acute
pulmonary embolism was less common in patients with a
nonoperable disease. These patients also had less massive
pulmonary embolism, which is in line with a more distal
disease and a possible process of in situ thrombosis.25 In this
registry, 12.4% of patients received a vena cava filter as a
treatment for recurrent acute pulmonary embolism and, as
previously reported,17 only 40.2% of operable patients had a
vena cava filter inserted, whereas this preoperative procedure
has been systematically applied in other patient series.8,26
Although CTEPH patients are a heterogeneous group with
respect to hemodynamic status and surgical accessibility of
pulmonary thromboemboli resulting in operability or nonop-
erability, they presented also with many similarities at diag-
nosis, suggesting an underlying common disease process. In
line with previous reports,8,14,15 CTEPH was almost equally
frequent in men and women in their sixth decade of life.
Operable patients were younger than nonoperable patients but
presented with similar disease severity as assessed by New
York Heart Association (NYHA) functional class. This is
consistent with findings from Bonderman et al,27 in a retro-
spective analysis of 181 European CTEPH patients, and from
Condliffe et al15 in a retrospective study of 469 CTEPH
patients from the United Kingdom. An increased awareness
of pulmonary embolism and of CTEPH as a subsequent
complication may be responsible for reduced time to diagno-
sis in both operable and nonoperable patients after the last
acute pulmonary embolism event (12.5 months) and the
symptom onset (14.1 months) compared with past studies
reporting a diagnostic delay of several years.28,29 The symp-
toms preceding the diagnosis of CTEPH have been described
previously,1 and did not differ in the present study. Effective
imaging technologies including conventional and CT pulmo-
nary angiography were widely used to examine large-vessel
occlusion, revealing a higher occurrence of proximal lesions
in the group of patients that was operable.
Chronic thromboembolic pulmonary hypertension patients
are characterized by numerous severe comorbidities.14,18,30 In
particular, chronic obstructive pulmonary disease was ob-
served in as many as 9.5% of the patients. A history of
splenectomy was more frequent in the CTEPH registry
patients than reported in patients with other chronic pulmo-
nary conditions,30 and was frequently associated with nonop-
erability (ie, with a distal type of CTEPH or a significant
comorbidity). This is in line with the postulated link between
abnormal postsplenectomy erythrocyte activities or abnormal
platelet activation and the development of a primarily distal
CTEPH disease.14,30 A history of cancer was reported in this
registry for 12% of the patients, which supports the concept
that malignancy and/or treatment for malignancy could be a
risk factor for CTEPH.14 A thrombophilic disorder was
present in nearly one third of the patients, and as reported
previously, CTEPH patients were more likely to have a blood
group other than 014; these observations were even more
pronounced in the operable group. A number of inherited and
acquired coagulation abnormalities have been identified in
recent years that may contribute to the development of
CTEPH. These include lupus anticoagulant and antiphospho-
lipid antibodies; deficiencies of protein C, protein S, and
antithrombin III; presence of factor V Leiden, and prothrom-
Table 6. PAH-Targeted Therapy Initiated at Diagnosis
All Patients
(n679)
Operable Patients*
(n427)
Nonoperable Patients*
(n247)
P
(Exploratory)
PAH-targeted therapy, % (n) 37.9 (676) 28.3 (427) 53.8 (247) 0.0001
Phosphodiesterase type V inhibitor, % 17.5 16.2 19.4 0.2923
Endothelin receptor antagonist, % 21.7 12.2 37.7 0.0001
Prostacyclin analogue, % 2.7 1.6 4.5 0.0443
Combination therapies, % 4.0 1.6 7.7 0.0002
P values from Fisher exact test. (n): patients with assessment. PAH indicates pulmonary arterial hypertension.
*Five patients had no data on operability.
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bin gene mutations.23,31,32 These abnormalities were identi-
fied in 27.7% of the registry patients and tended overall to be
more frequent in operable patients in line with more impaired
thromboemboli resolution. The current results confirm that
antiphospholipid antibodies, along with lupus anticoagulant,
2 thrombophilic factors associated with recurrent thrombo-
sis,33,34 are elevated in patients with CTEPH. However, a
prothrombotic pathogenic mechanism involving Factor VIII
in the development of CTEPH was not corroborated.35 A
detailed investigation of the risk factors involved in CTEPH
will be the subject of a separate publication.
This registry emphasizes the seriousness of the disease,
with 62 patients out of 679 documented as having died during
the observation period of the study (10 months). It also
reflects the changes that have occurred in the management of
CTEPH over recent years, including the increasing success rate
of PEA surgery and the availability of PAH-targeted therapies.
The low in-hospital mortality rate of 4.7% after surgery reported
here is in line with continuously improving surgical results in
recent worldwide series.8,15,27,36 Although surgical intervention
with PEA is the preferred treatment in eligible patients,
CTEPH patients may benefit from the pharmacotherapy that
has been developed for PAH.10,13 Despite the absence of
robust data from randomized, controlled trials, the prescrip-
tion of these medications, even in operable CTEPH, has
increased over the past years.15,37 Jensen et al37 reported an
increase in patients treated with PAH-targeted therapies
before PEA from 19.9% in 2005 to 37% in 2007. This change
in prescribing practice is confirmed by the present registry,
with 28.3% of the operable patients and 53.8% of the
nonoperable patients initiating at least 1 PAH-targeted ther-
apy at diagnosis. Because of unequal medical resources
and/or possibly different medical practices, these percentages
can be highly country dependent. Cautious use of PAH-
targeted therapies is, however, endorsed by current guide-
lines38: Preoperative treatment has been reported to have
minimal effect on pre-PEA hemodynamics and no effect on
post-PEA outcome,37 and may induce unnecessary delay to a
potentially curative surgical intervention.17
The limitations of the study are inherent to a registry
design: Some assessments were not systematically collected,
leading to underreporting (eg, blood groups and thrombotic
risk factors). Given that most of the participating centers were
referral centers for CTEPH and PEA, the proportion of
operable patients may have been overestimated because of
referral bias. Per country analyses have to be interpreted
cautiously, because the number of patients in some countries
could be small and not representative. Finally, no patient was
excluded from the analysis even when not satisfying the
inclusion criteria; as a consequence, 10 patients had no right
heart catheterization.
Conclusions
The similarities between operable and nonoperable CTEPH
patients necessitate a very careful diagnostic process with
high-quality angiography and right heart catheterization he-
modynamic evaluation to assess operability. Nevertheless,
operable and nonoperable CTEPH patients may differ relative
to the occurrence of associated medical conditions: In partic-
ular, thrombophilic disorders tend to be more frequent in
operable patients, whereas splenectomy and cancer are more
common in nonoperable patients. The registry data highlight
the importance of previous venous thromboembolism events
as a causal factor for the development of CTEPH, along with
a significant role for associated medical risk factors as
coexisting mechanisms in the disease process. A substantial
number of patients (operable and nonoperable) are currently
being treated with off-label treatments. The registry data also
indicate that, whereas PEA can be performed with a low
in-hospital mortality rate, operability rates may vary consid-
erably across centers and countries. The indication for PEA is
not clearly defined, and is dependent on the experience of the
surgical team. With surgical progress constantly extending
the selection of patients who can benefit from surgery, a
consensus among experts is needed to reassess the criteria for
operability. The ongoing 3-year follow-up of this large
patient cohort will make it possible to evaluate the impact of
the contemporary management of CTEPH on patient survival
compared with published series.
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CLINICAL PERSPECTIVE
We present short-term data from a large, prospective, international (mostly European) noninterventional registry of newly
diagnosed patients with chronic thromboembolic pulmonary hypertension, including operable and nonoperable cases. In
this registry, the diagnosis of chronic thromboembolic pulmonary hypertension was often delayed, with a median of 14
months after the initial symptoms. Three quarters of patients had a history of prior acute pulmonary embolism. One third
of patients received pulmonary endarterectomy with a mortality rate of 4.7%. Although clinical symptoms, New York
Heart Association class, and hemodynamics were not different between operable and nonoperable patients, nonoperable
patients were older, had a lower 6-minute walk test, had smaller pulmonary emboli in the past, were less likely to receive
thrombolytic therapy with their prior pulmonary embolus, and were more likely to have other causes of pulmonary
hypertension. The large difference in rates of pulmonary endarterectomy between countries suggests other local factors
influenced the decision to operate on patients with chronic thromboembolic pulmonary hypertension. The indication for
pulmonary endarterectomy is not clearly defined, and is dependent on the experience of the surgical team. About one third
of patients (operable and nonoperable) received off-label pulmonary hypertension–targeted treatments. Finally, these data
emphasize the deadly nature of the disease, with death documented for 62 patients out of 679 during the observation period
of the study (10 months).
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